Epidermal growth factor receptor (EGFR) mutations, amplification of MET, anaplastic lymphoma kinase (ALK), ROS1, and RET fusions are the representative driver oncogene of advanced NSCLC.4 Here, ALK is linked to non-small cell lung carcinoma.